RTP Mobile Logo
Breakfast with the Investigators: Exploring the Role of PARP Inhibition in the Management of Ovarian Cancer
Released July 2019

Proceedings from a CME symposium held at the 2019 ASCO Annual Meeting. Featuring perspectives from Prof Jonathan A Ledermann and Drs Joyce F Liu and David M O’Malley. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, gynecologic oncologists and other healthcare providers involved in the treatment of ovarian cancer (OC).

    Epithelial OC accounts for approximately 90% of malignant ovarian neoplasms, and this makes it the leading cause of death from gynecologic cancer in the United States. The most significant recent development in OC has been the introduction of PARP inhibitors into the therapeutic milieu. Important advances in the collective understanding of PARP inhibition as a mechanism to combat the development and progression of OC have led to the FDA approval of multiple PARP inhibitors in a number of clinical settings. The availability of PARP inhibitors has significant ramifications for practicing oncologists, who need to confront a variety of practical issues with regard to the safe and effective use of these agents.

    These video proceedings from a CME symposium held during the 2019 ASCO Annual Meeting feature discussions with leading researchers with an expertise in OC regarding actual cases from their practices and the published data that drive clinical decision-making for patients in those and diverse other situations. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist medical oncologists, gynecologic oncologists and other healthcare providers with the formulation of up-to-date clinical management strategies.


    • Appraise guideline recommendations, consensus statements and clinical investigator perspectives regarding the indications for and selection of genetic testing platforms in OC, and use the results of these assessments to guide long-term treatment planning, including clinical trial accrual.
    • Recognize the recent FDA approval of olaparib as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced OC and a deleterious or suspected deleterious BRCA germline or somatic mutation, and consider how the availability of this strategy affects current therapeutic algorithms.
    • Appreciate available clinical trial data with and approved indications for the use of FDA-endorsed PARP inhibitors for patients with platinum-sensitive and multiregimen-refractory OC in order to appropriately integrate these agents into routine clinical practice.
    • Recognize the toxicities associated with PARP inhibitors commonly used in the care of patients with OC, and offer supportive management strategies to minimize or ameliorate these side effects.
    • Develop an understanding of the mechanisms of action of, available data with and potential clinical roles for other investigational PARP inhibitors in preparation for their possible introduction into future clinical practice.
    • Recall the biologic rationale for and ongoing research efforts evaluating the role of PARP inhibitors in combination with chemotherapy, targeted therapy or immunotherapy, and refer appropriate patients for clinical trial participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Professor Jonathan A Ledermann
    Professor of Medical Oncology
    Clinical Director
    University College London Cancer Institute
    Director, Cancer Research UK and UCL Cancer Trials Centre
    London, United Kingdom

    Advisory Committee: Artios Pharma, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Cristal Therapeutics, Merck Sharp & Dohme Corp, Pfizer Inc, Roche Laboratories Inc, Seattle Genetics; Contracted Research: AstraZeneca Pharmaceuticals LP, Merck Sharp & Dohme Corp; Data and Safety Monitoring Board/Committee: Regeneron Pharmaceuticals Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology.

    Joyce F Liu, MD, MPH
    Assistant Professor of Medicine
    Harvard Medical School
    Director of Clinical Research, Division of Gynecologic Oncology
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Mersana Therapeutics, Tesaro.

    David M O’Malley, MD
    Medical Director, Gynecologic Oncology
    Director, Clinical Research, Gynecologic Oncology
    Co-Director, Gynecologic Oncology Phase I Program
    ORIEN Physician Liaison for OSUCCC – James
    The Ohio State University and The James Cancer Center
    Columbus, Ohio

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, GOG Foundation Inc, Janssen Biotech Inc, Myriad Genetic Laboratories Inc, Tesaro; Consulting Agreements: AbbVie Inc, Ambry Genetics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, ImmunoGen Inc, Partnership for Health Analytic Research LLC, Tesaro; Contracted Research: Agenus Inc, Ajinomoto, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, EMD Serono Inc, Ergomed PLC, Exelixis Inc, Genentech, GlaxoSmithKline, GOG Foundation Inc, ImmunoGen Inc, Janssen Biotech Inc, Ludwig Institute for Cancer Research Ltd, Novartis, PRA Health Sciences, Regeneron Pharmaceuticals Inc, Stemcentrx, Syneos Health, Tesaro, TRACON Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Marker Therapeutics Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Clovis Oncology and Tesaro.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: July 2019
    Expiration date: July 2020

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):